scholarly journals Habitat selection of the Ring OuzelTurdus torquatusin the Western Carpathians: the role of the landscape mosaic

Bird Study ◽  
2013 ◽  
Vol 60 (1) ◽  
pp. 22-34 ◽  
Author(s):  
Michał Ciach ◽  
Wojciech Mrowiec
2014 ◽  
Vol 83 (5) ◽  
pp. 1196-1205 ◽  
Author(s):  
Stephanie L. Eby ◽  
T. Michael Anderson ◽  
Emilian P. Mayemba ◽  
Mark E. Ritchie

Author(s):  
Stuart Sherburne ◽  
John Bissonette

This research project has two primary goals. The first is to determine home range spatial dynamics of marten (Maxes americana) in Yellowstone relative to habitat type. Results of this analysis will aid in the understanding of marten habitat selection. The study's second goal is aimed at identifying the habitat variables that influence subnivean access. A proximate factor analysis of subnivean access behavior will be conducted to determine the components that make old growth suitable for marten. Results from both objectives will allow assessment of the effects of the 1988 fires in Yellowstone on marten habitat.


2020 ◽  
Vol 251 ◽  
pp. 108794
Author(s):  
R. Tarjuelo ◽  
A. Benítez-López ◽  
F. Casas ◽  
C.A. Martín ◽  
J.T. García ◽  
...  

2010 ◽  
Author(s):  
Aja Taitano ◽  
Bradley Smith ◽  
Cade Hulbert ◽  
Kristin Batten ◽  
Lalania Woodstrom ◽  
...  

2016 ◽  
Vol 04 (01) ◽  
pp. 4-10

AbstractImmunosuppression permits graft survival after transplantation and consequently a longer and better life. On the other hand, it increases the risk of infection, for instance with cytomegalovirus (CMV). However, the various available immunosuppressive therapies differ in this regard. One of the first clinical trials using de novo everolimus after kidney transplantation [1] already revealed a considerably lower incidence of CMV infection in the everolimus arms than in the mycophenolate mofetil (MMF) arm. This result was repeatedly confirmed in later studies [2–4]. Everolimus is now considered a substance with antiviral properties. This article is based on the expert meeting “Posttransplant CMV infection and the role of immunosuppression”. The expert panel called for a paradigm shift: In a CMV prevention strategy the targeted selection of the immunosuppressive therapy is also a key element. For patients with elevated risk of CMV, mTOR inhibitor-based immunosuppression is advantageous as it is associated with a significantly lower incidence of CMV events.


Sign in / Sign up

Export Citation Format

Share Document